DE2518534A1 - N-methyl-n-(3,4,5-trimethoxybenzyl) -2,3-dimethyl-2,4-pentadienamine, verfahren zu ihrer herstellung sowie sie enthaltende arzneimittel - Google Patents
N-methyl-n-(3,4,5-trimethoxybenzyl) -2,3-dimethyl-2,4-pentadienamine, verfahren zu ihrer herstellung sowie sie enthaltende arzneimittelInfo
- Publication number
- DE2518534A1 DE2518534A1 DE19752518534 DE2518534A DE2518534A1 DE 2518534 A1 DE2518534 A1 DE 2518534A1 DE 19752518534 DE19752518534 DE 19752518534 DE 2518534 A DE2518534 A DE 2518534A DE 2518534 A1 DE2518534 A1 DE 2518534A1
- Authority
- DE
- Germany
- Prior art keywords
- trimethoxybenzyl
- formula
- chloride
- methyl
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 7
- MJFWGIGCSSZKIY-UHFFFAOYSA-N n,2,3-trimethyl-n-[(3,4,5-trimethoxyphenyl)methyl]penta-2,4-dien-1-amine Chemical compound COC1=CC(CN(C)CC(C)=C(C)C=C)=CC(OC)=C1OC MJFWGIGCSSZKIY-UHFFFAOYSA-N 0.000 title claims 2
- 238000004519 manufacturing process Methods 0.000 title description 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 claims description 11
- 125000005806 3,4,5-trimethoxybenzyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1C([H])([H])* 0.000 claims description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000000202 analgesic effect Effects 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 229910000000 metal hydroxide Inorganic materials 0.000 claims description 2
- 150000004692 metal hydroxides Chemical class 0.000 claims description 2
- XXRUQNNAKXZSOS-UHFFFAOYSA-N 5-(chloromethyl)-1,2,3-trimethoxybenzene Chemical compound COC1=CC(CCl)=CC(OC)=C1OC XXRUQNNAKXZSOS-UHFFFAOYSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 229940072033 potash Drugs 0.000 claims 1
- 235000015320 potassium carbonate Nutrition 0.000 claims 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229940124641 pain reliever Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 108010087765 Antipain Proteins 0.000 description 1
- NMKSBNZBSLHAKW-UHFFFAOYSA-N Cl.ClO Chemical compound Cl.ClO NMKSBNZBSLHAKW-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- -1 e.g. B Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- HSFHMJJDUVEWRQ-UHFFFAOYSA-N penta-2,4-dien-1-amine Chemical compound NCC=CC=C HSFHMJJDUVEWRQ-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES425970A ES425970A1 (es) | 1974-05-04 | 1974-05-04 | Un procedimiento para la obtencion de n - metil - n-(3,4,5-trimeboxibencil)-2,3-dimetil-2,4-pentadienamina. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2518534A1 true DE2518534A1 (de) | 1975-11-13 |
Family
ID=8466594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752518534 Pending DE2518534A1 (de) | 1974-05-04 | 1975-04-25 | N-methyl-n-(3,4,5-trimethoxybenzyl) -2,3-dimethyl-2,4-pentadienamine, verfahren zu ihrer herstellung sowie sie enthaltende arzneimittel |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JPS5337337B2 (enExample) |
| AR (1) | AR206623A1 (enExample) |
| AT (1) | AT337160B (enExample) |
| AU (1) | AU8050775A (enExample) |
| BE (1) | BE828240A (enExample) |
| CA (1) | CA1052794A (enExample) |
| CH (1) | CH615150A5 (enExample) |
| DE (1) | DE2518534A1 (enExample) |
| ES (1) | ES425970A1 (enExample) |
| FR (1) | FR2269336B1 (enExample) |
| GB (1) | GB1501153A (enExample) |
| NL (1) | NL7505254A (enExample) |
| SE (1) | SE412755B (enExample) |
| SU (1) | SU562192A3 (enExample) |
-
1974
- 1974-05-04 ES ES425970A patent/ES425970A1/es not_active Expired
-
1975
- 1975-01-01 AR AR257859A patent/AR206623A1/es active
- 1975-03-07 AT AT181075A patent/AT337160B/de not_active IP Right Cessation
- 1975-04-15 SE SE7504301A patent/SE412755B/xx unknown
- 1975-04-15 GB GB15514/75A patent/GB1501153A/en not_active Expired
- 1975-04-22 BE BE155654A patent/BE828240A/xx unknown
- 1975-04-24 AU AU80507/75A patent/AU8050775A/en not_active Expired
- 1975-04-25 DE DE19752518534 patent/DE2518534A1/de active Pending
- 1975-04-30 FR FR7513536A patent/FR2269336B1/fr not_active Expired
- 1975-05-01 CA CA226,057A patent/CA1052794A/en not_active Expired
- 1975-05-02 CH CH568075A patent/CH615150A5/de not_active IP Right Cessation
- 1975-05-02 NL NL7505254A patent/NL7505254A/xx not_active Application Discontinuation
- 1975-05-02 JP JP5380075A patent/JPS5337337B2/ja not_active Expired
- 1975-05-04 SU SU2129803A patent/SU562192A3/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| FR2269336B1 (enExample) | 1977-09-09 |
| SU562192A3 (ru) | 1977-06-15 |
| JPS50151835A (enExample) | 1975-12-06 |
| FR2269336A1 (enExample) | 1975-11-28 |
| ATA181075A (de) | 1976-10-15 |
| CA1052794A (en) | 1979-04-17 |
| AU8050775A (en) | 1976-10-28 |
| BE828240A (fr) | 1975-10-22 |
| AT337160B (de) | 1977-06-10 |
| JPS5337337B2 (enExample) | 1978-10-07 |
| ES425970A1 (es) | 1976-09-16 |
| NL7505254A (nl) | 1975-11-06 |
| CH615150A5 (en) | 1980-01-15 |
| GB1501153A (en) | 1978-02-15 |
| SE7504301L (sv) | 1975-11-05 |
| SE412755B (sv) | 1980-03-17 |
| AR206623A1 (es) | 1976-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2411382B2 (de) | 2-Tetrahydrofurfuryl-6,7-benzomorphane, Verfahren zur Herstellung und deren Verwendung | |
| DE1937477C3 (de) | I -Phenoxy-2-hydroxy-3-(l -methylcycloalkylamino)-propane, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| DE1720020A1 (de) | Verfahren zur Herstellung von N,N-disubstituierten Pyrrylaminoaethanolen | |
| DE2115926B2 (de) | 1-(4-hydroxy-3-dimethylaminosulfamidophenyl)-2-aminoaethanderivate, verfahren zu ihrer herstellung und diese enthaltende mittel | |
| DE2630060A1 (de) | 2-brom-6-fluor-n-2-imidazolidinyliden- benzamin, dessen saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu dessen herstellung | |
| DE2705416A1 (de) | Neue derivate des m-trifluormethylphenylpiperidins und deren salze, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
| DE1940566A1 (de) | 1-(2-Nitrilophenoxy)-2-hydroxy-3-aethylaminopropan und dessen Salze | |
| DE2518534A1 (de) | N-methyl-n-(3,4,5-trimethoxybenzyl) -2,3-dimethyl-2,4-pentadienamine, verfahren zu ihrer herstellung sowie sie enthaltende arzneimittel | |
| DD216454A5 (de) | Verfahren zur herstellung neuer dihydropyridine | |
| DE3643103A1 (de) | Substituierte benzamide, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| DE1931927A1 (de) | Neue Cyclohexylaminderivate | |
| DE2560602C2 (de) | Sauerstoffhaltige Diarylamidine | |
| DE1926754A1 (de) | Neue cyclische Verbindungen,ihre Herstellung und Verwendung | |
| DE2919553A1 (de) | Tetrahydroisochinolinderivat, verfahren zu seiner herstellung und es enthaltende arzneimittel | |
| DE2150977C3 (de) | Thienyl-aryl-propyl(3)-1 -phenyl-1 hydroxy-propyl(2)-amine, Verfahren zu ihrer Herstellung und deren Verwendung bei der Bekämpfung von Durchblutungsstörungen | |
| DE2518514A1 (de) | 1,3,4-trimethyl-2-(3,4,5-trimethoxybenzyl)-1,2,5,6-tetrahydropyridin, verfahren zu seiner herstellung sowie es enthaltende arzneimittel | |
| DE2530768C3 (de) | PhenoxyaUcylaminpyridyläther, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Präparate | |
| DE2705896B2 (de) | 23-disubstituierte Benzamide, Verfahren zu ihrer Herstellung sowie Mittel mit einem solchen Benzamid als Wirkstoff | |
| DE2807077B2 (de) | Verfahren zur Herstellung von 6,73,9, 10,11-Hexahydro-7,11 -methan-8,11-dimethylbenzo [b] thieno 2,3-d azocin | |
| DE2605913A1 (de) | Dimercaptoaethylaetherderivat, verfahren zu seiner herstellung und arzneimittel | |
| DE1770104C3 (de) | 2- [(3,4-Dichlorphenoxy)-methyl] -2-unidazolin und seine Salze | |
| DE2817399C3 (de) | Phenoxyessigsäurederivat, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitungen | |
| DE2454198C2 (de) | Isochinolin-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel | |
| DE2730312A1 (de) | (2-azabicyclo eckige klammer auf 2.2.2 eckige klammer zu octan-2-yl) diphenyl-alkanone, verfahren zu deren herstellung sowie dieselben enthaltende pharmazeutische praeparate | |
| DE1793590C3 (de) | N-Cyclopropyl-N-propargyl- 1-aminoindan, dessen Salze und Arzneimittel auf dieser Grundlage. Ausscheidung aus': 1443403 |